MENU
EMBC
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

EMBC stock forecast, quote, news & analysis

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes... Show more

EMBC
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for EMBC with price predictions
Jul 07, 2026

EMBC saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for EMBC moved out of overbought territory on July 01, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 41 similar instances where the indicator exited the overbought zone. In of the 41 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMBC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EMBC broke above its upper Bollinger Band on June 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for EMBC entered a downward trend on July 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EMBC's RSI Oscillator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on June 26, 2026. You may want to consider a long position or call options on EMBC as a result. In of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where EMBC advanced for three days, in of 225 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (4.514). P/E Ratio (1.693) is within average values for comparable stocks, (182.651). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.431). EMBC's Dividend Yield (0.144) is considerably higher than the industry average of (0.025). P/S Ratio (0.182) is also within normal values, averaging (76.829).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. EMBC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EMBC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Dividends

EMBC paid dividends on June 15, 2026

Embecta Corp EMBC Stock Dividends
А dividend of $0.01 per share was paid with a record date of June 15, 2026, and an ex-dividend date of May 28, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 8.2B. The market cap for tickers in the group ranges from 126 to 151.33B. ISRG holds the highest valuation in this group at 151.33B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 1%. For the same Industry, the average monthly price growth was 10%, and the average quarterly price growth was -9%. LUCY experienced the highest price growth at 61%, while RGNT experienced the biggest fall at -22%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 136%. For the same stocks of the Industry, the average monthly volume growth was 117% and the average quarterly volume growth was 91%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 66
Price Growth Rating: 54
SMR Rating: 84
Profit Risk Rating: 96
Seasonality Score: 11 (-100 ... +100)
View a ticker or compare two or three
EMBC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsOther

Profile
Details
Industry
N/A
Address
300 Kimball Drive
Phone
+1 862 401-0000
Employees
1850
Web
https://www.embecta.com
EMBC saw its Stochastic Oscillator leaves the overbought zone